


Phosphodiesterase-4 (PDE4) Inhibitor Market Projected to Grow at a Strong CAGR from 2020 to 2034 by DelveInsight

PDE4 Inhibitor companies are Arcutis Biotherapeutics, Chiesi Farmaceutici, Verona Pharma, Eisai, vTv Therapeutics, Tetra Therapeutics, Palobiofarma, etc

ALBANY, NY, UNITED STATES,
December 5, 2024 /EINPresswire.com/

-- The Phosphodiesterase-4 (PDE4) Inhibitor market size is anticipated to increase in the study period due to a direct consequence of an increase in R&D activity in the 7MM. Additionally, the competitive landscape is relatively sparse and the regulatory pathway for approval will likely involve extensive clinical trials to demonstrate safety and efficacy.



(Albany, USA) DelveInsight's Phosphodiesterase-4 (PDE4) Inhibitor Market Insights report includes a comprehensive understanding of current treatment practices, emerging Phosphodiesterase-4 (PDE4) Inhibitor, market share of individual therapies, and current and forecasted Phosphodiesterase-4 (PDE4) Inhibitor market size from 2020 to 2034, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Request for Sample Report @ [Phosphodiesterase-4 \(PDE4\) Inhibitor Market Analysis](#)

Key Takeaways from the Phosphodiesterase-4 (PDE4) Inhibitor Market Report

- As per DelveInsight's analysis, the Phosphodiesterase-4 (PDE4) Inhibitor market is anticipated to grow at a significant CAGR by 2034.
- Leading Phosphodiesterase-4 (PDE4) Inhibitor companies such as Arcutis Biotherapeutics, Chiesi Farmaceutici, Imara Inc, Verona Pharma, Eisai Inc, vTv Therapeutics, Tetra Therapeutics, Palobiofarma, and others are developing novel Phosphodiesterase-4 (PDE4) Inhibitors that can be available in the Phosphodiesterase-4 (PDE4) Inhibitor market in the coming years.
- Some of the key PDE4 inhibitors include Orismilast modified release tablets, CHF6001, Otezla,

Zatolmilast, TAK-279, PF-07038124, and Deucravacitinib, among others.

- In April 2024, Alto Neuroscience announced positive Phase I results for ALTO-101, a Novel PDE4 Inhibitor in development for Schizophrenia. Based on these data, the company is planning to initiate a trial evaluating ALTO101 in patients with cognitive impairment associated with schizophrenia in the first half of 2024.
- In September 2023, Shionogi announced the US Food and Drug Administration (FDA) has granted Tetra Therapeutics, a Shionogi Group Company, Rare Pediatric Disease Designation for zatolmilast (BPN14770), an investigational treatment being studied for Fragile X syndrome (FXS).
- In January 2023, UNION Therapeutics received FDA Fast Track designation for oral orismilast for the treatment of moderate to severe hidradenitis suppurativa.

Discover which therapies are expected to grab the Phosphodiesterase-4 (PDE4) Inhibitor market share @ Phosphodiesterase-4 (PDE4) Inhibitor Treatment Market -

https://www.delveinsight.com/report-store/phosphodiesterase-4-pde4-inhibitor-market-forecast?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=apr

Phosphodiesterase-4 (PDE4) Inhibitor Overview

Phosphodiesterase-4 (PDE4) inhibitors are a class of drugs designed to target and inhibit the activity of PDE4, an enzyme responsible for breaking down cyclic adenosine monophosphate (cAMP) in cells. By blocking PDE4, these inhibitors increase intracellular cAMP levels, leading to anti-inflammatory and immunomodulatory effects. PDE4 inhibitors are particularly valuable in managing chronic inflammatory and autoimmune diseases.

These inhibitors have shown efficacy in treating conditions such as chronic obstructive pulmonary disease (COPD), psoriasis, atopic dermatitis, and psoriatic arthritis. Apremilast and roflumilast are among the most widely recognized PDE4 inhibitors, with apremilast primarily used for psoriatic conditions and roflumilast for COPD management.

Despite their benefits, PDE4 inhibitors can cause side effects such as nausea, diarrhea, weight loss, and headaches, which may limit patient adherence. Additionally, their high cost can pose accessibility challenges.

Research is ongoing to develop next-generation PDE4 inhibitors with enhanced selectivity and reduced adverse effects. These advancements aim to expand therapeutic applications and improve patient outcomes. As more conditions are identified as being responsive to PDE4 modulation, these inhibitors are expected to play an increasingly significant role in the treatment of inflammatory diseases.

Learn more about the FDA-approved Phosphodiesterase-4 (PDE4) Inhibitor @ [Phosphodiesterase-4 \(PDE4\) Inhibitor Drugs](#)

Phosphodiesterase-4 (PDE4) Inhibitor Market Dynamics

The Phosphodiesterase-4 (PDE4) Inhibitor market dynamics are anticipated to change in the coming years. The enriching drug pipeline of Phosphodiesterase-4 (PDE4) Inhibitor holds significant potential for pharma companies to acquire a substantial market share, especially

given the unique and rich emerging pipelines. Phosphodiesterase-4 (PDE4) Inhibitor is particularly intriguing due to its involvement in critical steps that [explain its importance], especially in [relevant medical condition]. The existing knowledge and exposure to [related medical field] are expected to drive the adoption of Phosphodiesterase-4 (PDE4) Inhibitor upon approval. Despite the encouraging success of existing treatments, approximately a large number of prevalent cases remain unresponsive to single-agent therapy.

Furthermore, many potential therapies are being investigated for the treatment of [Indications], and it is safe to predict that the treatment space will significantly impact the Phosphodiesterase-4 (PDE4) Inhibitor market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the Phosphodiesterase-4 (PDE4) Inhibitor market in the [specific region or market].

Furthermore, the Phosphodiesterase-4 (PDE4) Inhibitor market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists.

Scope of the Phosphodiesterase-4 (PDE4) Inhibitor Market Report

- Coverage: 7MM
- Key Phosphodiesterase-4 (PDE4) Inhibitor Companies: Arcutis Biotherapeutics, Chiesi Farmaceutici, Imara Inc, Verona Pharma, Eisai Inc, vTv Therapeutics, Tetra Therapeutics, Palobiofarma, and others
- Key Phosphodiesterase-4 (PDE4) Inhibitor Pipeline Therapies: ARQ-151, Ensifentrine, and others.
- Phosphodiesterase-4 (PDE4) Inhibitor Therapeutic Assessment: Phosphodiesterase-4 (PDE4) Inhibitor current marketed and emerging therapies
- Phosphodiesterase-4 (PDE4) Inhibitor Market Dynamics: Attribute Analysis of Emerging Phosphodiesterase-4 (PDE4) Inhibitor Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Phosphodiesterase-4 (PDE4) Inhibitor Market Access and Reimbursement

Discover more about Phosphodiesterase-4 (PDE4) Inhibitor drugs in development @

[Phosphodiesterase-4 \(PDE4\) Inhibitor Clinical Trials and Advancements](#)

Table of Contents

1. Phosphodiesterase-4 (PDE4) Inhibitor Market Key Insights
2. Phosphodiesterase-4 (PDE4) Inhibitor Market Report Introduction
3. Phosphodiesterase-4 (PDE4) Inhibitor Market Overview at a Glance
4. Phosphodiesterase-4 (PDE4) Inhibitor Market Executive Summary
5. Disease Background and Overview
6. Phosphodiesterase-4 (PDE4) Inhibitor Treatment and Management
7. Phosphodiesterase-4 (PDE4) Inhibitor Epidemiology and Patient Population
8. Patient Journey

9. Phosphodiesterase-4 (PDE4) Inhibitor Marketed Drugs
10. Phosphodiesterase-4 (PDE4) Inhibitor Emerging Drugs
11. Seven Major Phosphodiesterase-4 (PDE4) Inhibitor Market Analysis
12. Phosphodiesterase-4 (PDE4) Inhibitor Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Trending Reports:

- Hearing Aid Devices Market: <https://www.delveinsight.com/report-store/hearing-aid-devices-market>
- Alport Syndrome Market: <https://www.delveinsight.com/report-store/alport-syndrome-market>
- Artificial Kidney Market: <https://www.delveinsight.com/report-store/artificial-kidney-market>
- Cardiac Restoration Systems Market: <https://www.delveinsight.com/report-store/cardiac-restoration-systems-market>
- Head And Neck Squamous Cell Carcinoma Market: <https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-market>

Ankit Nigam

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/766431935>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.